Introduction of a new drug/vaccine model against HIV-1 with prophylactic and therapeutic actions, also useful, in HIV-1 rehabilitation. This RNA-peptide vaccine projects involving RNA from SARS-CoV-2, and peptides from human HIV-1 and human PARP-1 proteins. As mRNA target, we used primers miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs. The primers were modified with poly adenine (A) target. We designed the peptides target from HIV-1 protein and PARP-1 human protein. Our analysis, according to the algorithms Cruz Rodriguez (CR) identified an RNA-peptide with theorical fusion value stability FS=80.04 cruz, EA= 97.22 ro and BA= 1.21 to treat HIV-1. Where, we are proposing, the exosomes and how these vesicles could function as carriers of our RNA-peptide molecule. In this study, we expect that major histocompatibility complex l (MHC l) bind the molecule peptide (B) generated by hydrolysis (DEVD) of molecule RNA-peptide (AB) after induction of apoptosis pathways by caspase 3 or caspase 7. Also, we expect that major histocompatibility complex ll (MHC ll) bind the molecule RNA-peptide (A) generated and recognition by appropriate T-cells at the infected cell with HIV-1.
A Novel Vaccine RNA-peptide against HIV-1: Exosomes as Carrier in Viral Progression